Xeris Biopharma Holdings, Inc. current report, 09 May 2023

Full document

Xeris Biopharma Holdings, Inc. — Form 8-K Summary

Business Context and Reporting Period

On May 9, 2023, Xeris Biopharma Holdings, Inc. furnished a Form 8-K reporting that it had issued a press release regarding results of operations and business highlights for the three months ended March 31, 2023.

The filing concerns Item 2.02, Results of Operations and Financial Condition. The underlying press release was furnished as Exhibit 99.1, but its financial and operating details are not included in the provided filing text.

Financial Metrics

  • Revenue: The filing text does not provide a clear value.
  • Profit or loss: The filing text does not provide a clear value.
  • Cash flow: The filing text does not provide a clear value.
  • Margins: The filing text does not provide a clear value.
  • Debt and liquidity: The filing text does not provide a clear value.
  • Other key financial metrics: The filing text does not provide a clear value.

Material Changes Versus the Prior Comparable Period

The filing states that the press release contained first-quarter 2023 results and business highlights, but it does not provide the underlying comparisons or quantify changes from the prior-year period.

Guidance, Outlook, Risks, and Unusual Items

The provided filing text does not include guidance, outlook, management commentary, risk updates, contingencies, or unusual items. These matters may have been discussed in Exhibit 99.1, which is not reproduced in the source content.

Important Facts to Verify

  • Review Exhibit 99.1 for first-quarter 2023 revenue, earnings, cash flow, liquidity, debt, and operating metrics.
  • Verify year-over-year and sequential changes reported in the press release.
  • Check for full-year guidance, revised outlook, and management commentary.
  • Confirm any non-GAAP measures and reconciliations presented in the press release.
  • Note that the Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference, except where expressly stated.